{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:10:31Z","timestamp":1787901031329,"version":"build-2784847793"},"reference-count":168,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Glioblastoma is the most common histologic type of all gliomas and contributes to 57.3% of all cases. Despite the standard management based on surgical resection and radiotherapy, it is related to poor outcome, with a 5-year relative survival rate below 6.9%. In order to improve the overall outcome for patients, the new therapeutic strategies are needed. Herein, we describe the current state of knowledge on novel targeted therapies in glioblastoma. Based on recent studies, we compared treatment efficacy measured by overall survival and progression-free survival in patients treated with selected potential antitumor drugs. The results of the application of the analyzed inhibitors are highly variable despite the encouraging conclusions of previous preclinical studies. This paper focused on drugs that target major glioblastoma kinases. As far, the results of some BRAF inhibitors are favorable. Vemurafenib demonstrated a long-term efficacy in clinical trials while the combination of dabrafenib and trametinib improves PFS compared with both vemurafenib and dabrafenib alone. There is no evidence that any MEK inhibitor is effective in monotherapy. According to the current state of knowledge, BRAF and MEK inhibition are more advantageous than BRAF inhibitor monotherapy. Moreover, mTOR inhibitors (especially paxalisib) may be considered a particularly important group. Everolimus demonstrated a partial response in a significant proportion of patients when combined with bevacizumab, however its actual role in the treatment is unclear. Neither nintedanib nor pemigatinib were efficient in treatment of GBM. Among the anti-VEGF drugs, bevacizumab monotherapy was a well-tolerated option, significantly associated with anti-GBM activity in patients with recurrent GBM. The efficacy of aflibercept and pazopanib in monotherapy has not been demonstrated. Apatinib has been proven to be effective and tolerable by a single clinical trial, but more research is needed. Lenvatinib is under trial. Finally, promising results from a study with regorafenib may be confirmed by the ongoing randomized AGILE trial. The studies conducted so far have provided a relatively wide range of drugs, which are at least well tolerated and demonstrated some efficacy in the randomized clinical trials. The comprehensive understanding of the molecular biology of gliomas promises to further improve the treatment outcomes of patients.<\/jats:p>","DOI":"10.3390\/cancers14215377","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T23:26:32Z","timestamp":1667258792000},"page":"5377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["New Directions in the Therapy of Glioblastoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-3574","authenticated-orcid":false,"given":"Katarzyna","family":"Szklener","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, 8 Jaczewski Street, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Mazurek","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Wieteska","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, 8 Jaczewski Street, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Wac\u0142awska","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, 8 Jaczewski Street, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-3028","authenticated-orcid":false,"given":"Mateusz","family":"Bilski","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Ma\u0144dziuk","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, 8 Jaczewski Street, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2015.05.005","article-title":"Glioblastoma multiforme: Pathogenesis and treatment","volume":"152","author":"Alifieris","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: A \u201cstate of the science\u201d review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-12048-5_1","article-title":"Epidemiology of gliomas","volume":"163","author":"Ostrom","year":"2015","journal-title":"Cancer Treat Res."},{"key":"ref_5","unstructured":"(2022, July 09). Types of Brain Tumours. Available online: https:\/\/www.aans.org\/en\/Patients\/Neurosurgical-Conditions-and-Treatments\/Brain-Tumors."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"748061","DOI":"10.3389\/fonc.2021.748061","article-title":"Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975\u20132018","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chen, B., Chen, C., Zhang, Y., and Xu, J. (2021). Recent incidence trend of elderly patients with glioblastoma in the United States, 2000\u20132017. BMC Cancer, 21.","DOI":"10.1186\/s12885-020-07778-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/neuonc\/now288","article-title":"Genotype-based gene signature of glioma risk","volume":"19","author":"Huang","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer Statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s12094-020-02340-8","article-title":"A comprehensive overview on the molecular biology of human glioma: What the clinician needs to know","volume":"22","author":"Gargini","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/CCO.0000000000000483","article-title":"Diffuse Low-Grade Glioma, Oncological Outcome and Quality of Life: A Surgical Perspective","volume":"30","author":"Duffau","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","article-title":"Survival in Glioblastoma: A Review on the Impact of Treatment Modalities","volume":"18","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8013575","DOI":"10.1155\/2017\/8013575","article-title":"Diagnostic and therapeutic biomarkers in glioblastoma: Current status and future perspectives","volume":"2017","author":"Szopa","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/cns.13.65","article-title":"Symptom management and quality of life in glioma patients","volume":"3","author":"Boele","year":"2014","journal-title":"CNS Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5604\/01.3001.0014.2473","article-title":"Current Strategies for the Treatment of Malignant Gliomas\u2014Experience of the Department of Neurosurgery, Brodno Masovian Hospital in Warsaw","volume":"92","author":"Turek","year":"2020","journal-title":"Pol. J. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: Overview of Disease and Treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101896","DOI":"10.1016\/j.ctrv.2019.101896","article-title":"Molecular targeted therapy of glioblastoma","volume":"80","author":"Preusser","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12094-017-1763-6","article-title":"SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)","volume":"20","author":"Carrato","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1590\/1806-9282.65.3.424","article-title":"Metastasis from glioblastoma multiforme: A meta-analysis","volume":"65","author":"Cunha","year":"2019","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential strategies overcoming the temozolomide resistance for glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol. Med. Chir."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11912-019-0783-5","article-title":"Evidence-Based Practice: Temozolomide Beyond Glioblastoma","volume":"21","author":"Chua","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., and Cheng, S.-Y. (2021). The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. Cells, 10.","DOI":"10.3390\/cells10030484"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13046-022-02431-0","article-title":"PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C\/EBP\u03b2 degradation to facilitate proneural-to-mesenchymal transition","volume":"41","author":"Gao","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/neuonc\/now102","article-title":"The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma","volume":"18","author":"Lamure","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/PPO.0000000000000326","article-title":"Bevacizumab and glioblastoma: Past, present, and future directions","volume":"24","author":"Kim","year":"2018","journal-title":"Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","article-title":"Emerging therapies for glioblastoma: Current state and future directions","volume":"41","author":"Rong","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2741\/4362","article-title":"Glioma: An Overview of Current Classifications, Characteristics, Molecular Biology and Target Therapies","volume":"20","author":"Zeng","year":"2015","journal-title":"Front. Biosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rajaratnam, V., Islam, M.M., Yang, M., Slaby, R., Ramirez, H.M., and Mirza, S.P. (2020). Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Cancers, 12.","DOI":"10.3390\/cancers12040937"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4103\/jnrp.jnrp_168_17","article-title":"A simplified overview of World Health Organization classification update of central nervous system tumors 2016","volume":"8","author":"Gupta","year":"2017","journal-title":"J. Neurosci. Rural Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","article-title":"Ten-year survival in glioblastoma. A systematic review","volume":"54","author":"Tykocki","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"ref_39","first-page":"3","article-title":"Glioblastoma Multiforme: A Review of Its Epidemiology and Pathogenesis through Clinical Presentation and Treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jocn.2010.02.015","article-title":"Glioblastoma of the cerebellum and brainstem","volume":"17","author":"Stark","year":"2010","journal-title":"J Clin Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/erm.12.30","article-title":"The cellular origin for malignant glioma and prospects for clinical advancements","volume":"12","author":"Zong","year":"2012","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_42","first-page":"665","article-title":"Establish six-gene prognostic model for glioblastoma based on multi-omics data of TCGA database","volume":"43","author":"Lei","year":"2021","journal-title":"Yi Chuan"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100051","DOI":"10.1016\/j.cmpbup.2022.100051","article-title":"Identification of key genes associated with survival of glioblastoma multiforme using integrated analysis of TCGA datasets","volume":"2","author":"Redekar","year":"2022","journal-title":"Comput. Methods Programs Biomed. Update"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuro.2012.11.001","article-title":"Discovering gene\u2013environment interactions in glioblastoma through a comprehensive data integration bioinformatics method","volume":"35","author":"Kunkle","year":"2013","journal-title":"Neurotoxicology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Fabro, F., Lamfers, M.L.M., and Leenstra, S. (2022). Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14030600"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1038\/s41598-020-64289-6","article-title":"The limitations of targeting MEK signalling in Glioblastoma therapy","volume":"10","author":"Selvasaravanan","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"772052","DOI":"10.3389\/fonc.2021.772052","article-title":"BRAF Signaling Iinhibition in Glioblastoma: Which Clinical Perspectives?","volume":"11","author":"Aldegheri","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11523-020-00735-9","article-title":"Clinical relevance of BRAF V600E mutation status in brain tumors with a focus on a novel management algorithm","volume":"15","author":"Kowalewski","year":"2020","journal-title":"Target. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41388-021-02056-1","article-title":"Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma","volume":"41","author":"Alzial","year":"2022","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"19999","DOI":"10.1038\/s41598-021-99278-w","article-title":"BRAF mutations may identify a clinically distinct subset of glioblastoma","volume":"11","author":"McNulty","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1902971","DOI":"10.1002\/advs.201902971","article-title":"Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment","volume":"7","author":"Medina","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.18632\/oncotarget.26932","article-title":"Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: A report of two cases","volume":"10","author":"Woo","year":"2019","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"574974","DOI":"10.3389\/fonc.2020.574974","article-title":"BRAF alteration in central and peripheral nervous system tumors","volume":"10","author":"Srinivasa","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lokhandwala, P.M., Tseng, L.H., Rodriguez, E., Zheng, G., Pallavajjalla, A., Gocke, C.D., Eshleman, J.R., and Lin, M.T. (2019). Clinical Mutational Profiling and Categorization of BRAF Mutations in Melanomas Using Next Generation Sequencing. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5864-1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2017.7032","article-title":"Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma","volume":"16","author":"Johanns","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"451","DOI":"10.6004\/jnccn.2018.7029","article-title":"BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults","volume":"16","author":"Johanns","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., and Maddalena, P. (2020). BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers, 12.","DOI":"10.3390\/cancers12071823"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","article-title":"BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study","volume":"36","author":"Kaley","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): A multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11523-022-00888-9","article-title":"Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I\/II Study","volume":"17","author":"Trippett","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1200\/JCO.2022.40.16_suppl.2047","article-title":"Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results","volume":"40","author":"Wen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A Randomized Phase II Study of Everolimus in Combination with Chemoradiation in Newly Diagnosed Glioblastoma: Results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","article-title":"A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K","volume":"17","author":"Ma","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_65","first-page":"240","article-title":"Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab\/everolimus as First-Line Treatment for Patients with Glioblastoma","volume":"10","author":"Hainsworth","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-014-1631-y","article-title":"Phase II Trial of Triple Tyrosine Kinase Receptor Inhibitor Nintedanib in Recurrent High-Grade Gliomas","volume":"121","author":"Norden","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"ref_67","unstructured":"(2022, July 31). Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05267106?term=pemigatinib&cond=glioblastoma&draw=2&rank=1."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2010.34.1636","article-title":"Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study","volume":"29","author":"Lamborn","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in Progressive Glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noq025","article-title":"Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)","volume":"12","author":"Iwamoto","year":"2010","journal-title":"Neuro-Oncology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1002\/cncr.25275","article-title":"Concurrent Radiotherapy and Temozolomide Followed by Temozolomide and Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme","volume":"116","author":"Hainsworth","year":"2010","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-010-0217-6","article-title":"Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma","volume":"101","author":"Reardon","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/neuonc\/nos322","article-title":"NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme","volume":"15","author":"Peereboom","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"v157","DOI":"10.1093\/annonc\/mdz243.046","article-title":"A phase II\/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: The STELLAR study","volume":"30","author":"Brahm","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2271","article-title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","volume":"31","author":"Lwin","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10579","DOI":"10.2147\/OTT.S226804","article-title":"Apatinib plus temozolomide for recurrent glioblastoma: An uncontrolled, open-label study","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/13543776.2017.1339688","article-title":"Discovery of small-molecule ATR inhibitors for potential cancer treatment: A patent review from 2014 to present","volume":"27","author":"Mahapatra","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Cheng, Y., and Tian, H. (2017). Current development status of MEK inhibitors. Molecules, 22.","DOI":"10.3390\/molecules22101551"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","article-title":"MEK in cancer and cancer therapy","volume":"141","author":"Neuzillet","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting Alterations in the RAF-MEK Pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., and Wei, X. (2022). Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. Genes Dis.","DOI":"10.1016\/j.gendis.2022.05.006"},{"key":"ref_85","first-page":"vdaa138","article-title":"Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma","volume":"2","author":"Schreck","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"415","DOI":"10.20892\/j.issn.2095-3941.2019.0137","article-title":"Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy","volume":"16","author":"Li","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"760055","DOI":"10.3389\/fphar.2021.760055","article-title":"Trametinib Inhibits the Growth and Aerobic Glycolysis of Glioma Cells by Targeting the PKM2\/c-Myc Axis","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Shannon, S., Jia, D., Entersz, I., Beelen, P., Yu, M., Carcione, C., Carcione, J., Mahtabfar, A., Vaca, C., and Weaver, M. (2017). Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3107-x"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Colardo, M., Segatto, M., and Di Bartolomeo, S. (2021). Targeting RTK-PI3K-mTOR axis in gliomas: An update. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094899"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"749242","DOI":"10.3389\/fphar.2021.749242","article-title":"The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway","volume":"12","author":"Ji","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5560915","DOI":"10.1155\/2021\/5560915","article-title":"Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme","volume":"2021","author":"Yao","year":"2021","journal-title":"J. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12943-017-0670-3","article-title":"Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"33440","DOI":"10.18632\/oncotarget.7961","article-title":"PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.apsb.2021.05.019","article-title":"A Novel PI3K Inhibitor XH30 Suppresses Orthotopic Glioblastoma and Brain Metastasis in Mice Models","volume":"12","author":"Ji","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Farooq, M., Khan, A.W., Kim, M.S., and Choi, S. (2021). The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration. Cells, 10.","DOI":"10.3390\/cells10113242"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Jimenez-Pascual, A., and Siebzehnrubl, F.A. (2019). Fibroblast Growth Factor Receptor Functions in Glioblastoma. Cells, 8.","DOI":"10.3390\/cells8070715"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40478-021-01170-1","article-title":"Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs","volume":"9","author":"Georgescu","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cam4.268","article-title":"Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy","volume":"3","author":"Ye","year":"2014","journal-title":"Cancer Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"538","DOI":"10.21037\/atm.2016.11.65","article-title":"Uncovering the influence of the FGFR1 pathway on glioblastoma radiosensitivity","volume":"4","author":"Sayal","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1053\/j.seminoncol.2015.09.027","article-title":"Fibroblast growth factor (FGF) receptor\/FGF inhibitors: Novel targets and strategies for optimization of response of solid tumors","volume":"42","author":"Hierro","year":"2015","journal-title":"Semin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3892\/or.2014.3283","article-title":"Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma","volume":"32","author":"Ohashi","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e98772","DOI":"10.15252\/embj.201798772","article-title":"Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma","volume":"37","author":"Siebzehnrubl","year":"2018","journal-title":"EMBO J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-022-01363-2","article-title":"Fibroblast growth factor receptor 4 promotes glioblastoma progression: A central role of integrin-mediated cell invasiveness","volume":"10","author":"Gabler","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Ardizzone, A., Scuderi, S.A., Giuffrida, D., Colarossi, C., Puglisi, C., Campolo, M., Cuzzocrea, S., Esposito, E., and Paterniti, I. (2020). Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma. Cancers, 12.","DOI":"10.3390\/cancers12123825"},{"key":"ref_108","first-page":"25","article-title":"Angiogenesis-possibilities, problems and prospects","volume":"61","author":"Kurzyk","year":"2015","journal-title":"Postepy Biochem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42047-020-00060-5","article-title":"The immunohistochemical landscape of the VEGF family and its receptors in glioblastomas","volume":"3","author":"Loureiro","year":"2020","journal-title":"Surg. Exp. Pathol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"19550","DOI":"10.1038\/s41598-021-98911-y","article-title":"A vascularized tumoroid model for human glioblastoma angiogenesis","volume":"11","author":"Tatla","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2017.01.010","article-title":"Hypoxia-mediated mechanisms associated with antiangiogenic treatment resistance in glioblastomas","volume":"187","author":"Mahase","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"\u0218ovrea, A.S., Bo\u0219ca, B., Melincovici, C.S., Constantin, A.M., Crintea, A., M\u0103rginean, M., Dronca, E., Jianu, M.E., Sufle\u021bel, R., and Gonciar, D. (2022). Multiple Faces of the Glioblastoma Microenvironment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020595"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Rosi\u0144ska, S., and Gavard, J. (2021). Tumor Vessels Fuel the Fire in Glioblastoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126514"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"622615","DOI":"10.3389\/fphys.2021.622615","article-title":"The Normal and Brain Tumor Vasculature: Morphological and Functional Characteristics and Therapeutic Targeting","volume":"12","author":"Guyon","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14737140.2017.1322903","article-title":"Angiogenesis inhibitors in tackling recurrent glioblastoma","volume":"17","author":"Hundsberger","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","article-title":"Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma","volume":"57","author":"Ahir","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","article-title":"The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1159\/000504929","article-title":"Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report","volume":"12","author":"Mohamed","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/neuonc\/noaa258","article-title":"IDH-Wildtype Lower-Grade Diffuse Gliomas: The Importance of Histological Grade and Molecular Assessment for Prognostic Stratification","volume":"23","author":"Berzero","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.114.058339","article-title":"Factors influencing the CNS distribution of a novel MEK-1\/2 inhibitor: Implications for combination therapy for melanoma brain metastases","volume":"42","author":"Vaidhyanathan","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: Implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_123","first-page":"PO.19.00272","article-title":"Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma","volume":"4","author":"Kushnirsky","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"ref_126","unstructured":"(2022, July 25). FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for Unresectable or Metastatic Solid Tumours with BRAF V600E Mutation. Available online: https:\/\/www.esmo.org\/oncology-news\/fda-grants-accelerated-approval-to-dabrafenib-in-combination-with-trametinib-for-unresectable-or-metastatic-solid-tumours-with-braf-v600e-mutation."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"viii132","DOI":"10.1093\/annonc\/mdy273.395","article-title":"Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600\u2013mutant high-grade glioma (HGG) or low-grade glioma (LGG)","volume":"29","author":"Hargrave","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_128","unstructured":"(2022, July 28). Cobimetinib Approved for Advanced Melanoma\u2013National Cancer Institute, Available online: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2015\/cobimetinib-melanoma."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Cruz Da Silva, E., Mercier, M.C., Etienne-Selloum, N., Dontenwill, M., and Choulier, L. (2021). A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers, 13.","DOI":"10.3390\/cancers13081795"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-19-2808","article-title":"First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K\/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma","volume":"26","author":"Wen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: Triple Angiokinase Inhibitor With Sustained Receptor Blockade and Good Antitumor Efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e2100371","DOI":"10.1200\/PO.21.00371","article-title":"Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation","volume":"6","author":"Capone","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bcp.2019.07.021","article-title":"Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF\/ERK pathway","volume":"168","author":"Lazzara","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.ijrobp.2006.11.011","article-title":"VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma","volume":"67","author":"Wachsberger","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11060-016-2357-9","article-title":"Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas","volume":"132","author":"Nayak","year":"2017","journal-title":"J. Neuro-Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/cns.15.8","article-title":"Use of bevacizumab in recurrent glioblastoma","volume":"4","author":"Ghiaseddin","year":"2015","journal-title":"CNS Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Romero, N., Palac\u00edn-Aliana, I., Madurga, R., Carri\u00f3n-Navarro, J., Esteban-Rubio, S., Jim\u00e9nez, B., Collazo, A., P\u00e9rez-Rodr\u00edguez, F., Ortiz de Mendivil, A., and Fern\u00e1ndez-Carballal, C. (2020). Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. BMC Med., 18.","DOI":"10.1186\/s12916-020-01610-0"},{"key":"ref_138","first-page":"e51638","article-title":"Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma","volume":"92","author":"Omar","year":"2014","journal-title":"J. Vis. Exp."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/HYPERTENSIONAHA.120.16454","article-title":"Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial","volume":"77","author":"McGeoch","year":"2021","journal-title":"Hypertension"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.18.00725","article-title":"Phase 1 dose-escalation study of once weekly or once every two weeks administration of high dose sunitinib in patients with refractory solid tumors","volume":"37","author":"Rovithi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1078-0432.CCR-21-1933","article-title":"Tumor Drug Concentration and Phosphoproteomic Profiles after Two Weeks of Treatment with Sunitinib in Patients with Newly-Diagnosed Glioblastoma","volume":"28","author":"Labots","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41419-021-04225-2","article-title":"Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1\/myosin heavy chain 9 axis","volume":"12","author":"Yao","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_143","unstructured":"(2022, September 21). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03970447."},{"key":"ref_144","unstructured":"(2022, September 21). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial","volume":"13","author":"Marosi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and\/or Frail Patients with Newly Diagnosed Glioblastoma Multiforme","volume":"33","author":"Roa","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas","volume":"28","author":"Fogh","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_150","first-page":"e18480","article-title":"Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme: A Retrospective Multi-Institutional Experience","volume":"13","author":"Lovo","year":"2021","journal-title":"Cureus"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000505706","article-title":"Stereotactic radiotherapy in recurrent glioblastoma: A valid salvage treatment option","volume":"98","author":"Yaprak","year":"2020","journal-title":"Stereotact. Funct. Neurosurg."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): A systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11060-015-1745-x","article-title":"Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas","volume":"122","author":"Minniti","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.ijrobp.2019.06.539","article-title":"Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology\/RTOG 1205): Initial outcomes and RT plan quality report","volume":"105","author":"Tsien","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_156","first-page":"33","article-title":"The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma","volume":"22","author":"Chan","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ijrobp.2017.06.2466","article-title":"Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy with Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma","volume":"99","author":"Clarke","year":"2017","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2019.06.009","article-title":"Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma","volume":"138","author":"Fleischmann","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.nano.2017.06.004","article-title":"Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma","volume":"13","author":"Kievit","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Lehrer, E.J., Ruiz-Garcia, H., Nehlsen, A.D., Sindhu, K.K., Estrada, R.S., Borst, G.R., Sheehan, J.P., Quinones-Hinojosa, A., and Trifiletti, D.M. (2022). Preoperative Stereotactic Radiosurgery for Glioblastoma. Biology, 11.","DOI":"10.3390\/biology11020194"},{"key":"ref_162","unstructured":"(2022, August 20). Preoperative Radiosurgery for the Treatment of High Grade Glioma, The NeoGlioma Study, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT05030298?view=record."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.ijrobp.2008.10.035","article-title":"Three-Staged Stereotactic Radiotherapy without Whole Brain Irradiation for Large Metastatic Brain Tumors","volume":"74","author":"Higuchi","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_164","first-page":"e5472","article-title":"Two-session Radiosurgery as Initial Treatment for Newly Diagnosed Large, Symptomatic Brain Metastases from Breast and Lung Histology","volume":"11","author":"Lovo","year":"2019","journal-title":"Cureus"},{"key":"ref_165","first-page":"e2141","article-title":"Staged Image-guided Robotic Radiosurgery and Deferred Chemotherapy to Treat a Malignant Glioma During and After Pregnancy","volume":"10","author":"Romanelli","year":"2018","journal-title":"Cureus"},{"key":"ref_166","first-page":"e7850","article-title":"Two-Session Radiosurgery for Large Primary Tumors Affecting the Brain","volume":"12","author":"Lovo","year":"2020","journal-title":"Cureus"},{"key":"ref_167","unstructured":"Lovo, E.E. (2022, January 19\u201323). Pros and cons for staged SRS vs fractionation for large brain metastasis. Proceedings of the 15th International Stereotactic Radiosurgery Society Congress (ISRS 2022), Milan, Italy."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1470-2045(18)30827-1","article-title":"Drug development for glioma: Are we repeating the same mistakes?","volume":"20","author":"Stupp","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:07:01Z","timestamp":1760144821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":168,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14215377"],"URL":"https:\/\/doi.org\/10.3390\/cancers14215377","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}